Xavier Castellsagué

ORCID: 0000-0002-0802-3595
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cervical Cancer and HPV Research
  • Genital Health and Disease
  • Head and Neck Cancer Studies
  • Hepatitis B Virus Studies
  • Endometrial and Cervical Cancer Treatments
  • Esophageal Cancer Research and Treatment
  • Urological Disorders and Treatments
  • Global Cancer Incidence and Screening
  • Cancer Risks and Factors
  • Colorectal and Anal Carcinomas
  • Reproductive tract infections research
  • Oral Health Pathology and Treatment
  • Cancer-related molecular mechanisms research
  • Alcohol Consumption and Health Effects
  • Lung Cancer Treatments and Mutations
  • Cancer-related Molecular Pathways
  • Folate and B Vitamins Research
  • Nutritional Studies and Diet
  • RNA modifications and cancer
  • Urologic and reproductive health conditions
  • Genetic Associations and Epidemiology
  • Viral-associated cancers and disorders
  • Molecular Biology Techniques and Applications
  • Cancer Diagnosis and Treatment
  • Multiple and Secondary Primary Cancers

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2010-2023

Institut Català d'Oncologia
2012-2023

Centre international de recherche sur le cancer
1994-2023

Queen Mary University of London
2023

Institut d'Investigació Biomédica de Bellvitge
2011-2022

Centro de Investigación Biomédica en Red
2010-2022

Danish Cancer Society
2011-2018

Institut National de Santé Publique du Québec
2018

Royal Women's Hospital
2018

Murdoch Children's Research Institute
2018

Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but risk associated various HPV types has not been adequately assessed.We pooled data from 11 case-control studies nine countries involving 1918 women histologically confirmed squamous-cell cancer and 1928 control women. A common protocol questionnaire were used. Information on factors was obtained by personal interviews, cells collected for detection DNA typing in a central laboratory...

10.1056/nejmoa021641 article EN New England Journal of Medicine 2003-02-05

Abstract Background: The magnitude of risk conferred by the interaction between tobacco and alcohol use on head neck cancers is not clear because studies have used various methods to quantify excess cancer burden. Methods: We analyzed individual-level pooled data from 17 European American case-control (11,221 cases 16,168 controls) participating in International Head Neck Cancer Epidemiology consortium. estimated multiplicative parameter (ψ) population attributable risks (PAR). Results: A...

10.1158/1055-9965.epi-08-0347 article EN Cancer Epidemiology Biomarkers & Prevention 2009-02-01

Abstract At least 15 types of HPV have been associated with cervical cancer, but current vaccines confer only type‐specific immunity. To determine geographic variations in the type distribution we carried out a pooled analysis data from an international survey cancer and multicenter case‐control study, both co‐coordinated by IARC. Study cases were 3,607 women incident, histologically confirmed recruited 25 countries. DNA detection typing cells or biopsies centrally done using PCR assays....

10.1002/ijc.20244 article EN International Journal of Cancer 2004-04-12

At least 75% of head and neck cancers are attributable to a combination cigarette smoking alcohol drinking. A precise understanding the independent association each these factors in absence other with risk cancer is needed elucidate mechanisms carcinogenesis assess efficacy interventions aimed at controlling either factor. We examined extent which associated among never drinkers drinking users tobacco. pooled individual-level data from 15 case–control studies that included 10244 case...

10.1093/jnci/djk179 article EN JNCI Journal of the National Cancer Institute 2007-05-15

It is uncertain whether male circumcision reduces the risks of penile human papillomavirus (HPV) infection in man and cervical cancer his female partner.

10.1056/nejmoa011688 article EN New England Journal of Medicine 2002-04-11

Since 2006, many countries have implemented publicly funded human papillomavirus (HPV) immunisation programmes. However, global estimates of the extent and impact vaccine coverage are still unavailable. We aimed to quantify worldwide cumulative HPV programmes up 2014, potential on future cervical cancer cases deaths.

10.1016/s2214-109x(16)30099-7 article EN cc-by The Lancet Global Health 2016-06-21

We conducted a large international study to estimate fractions of head and neck cancers (HNCs) attributable human papillomavirus (HPV-AFs) using six HPV-related biomarkers viral detection, transcription, cellular transformation. Formalin-fixed, paraffin-embedded cancer tissues the oral cavity (OC), pharynx, larynx were collected from pathology archives in 29 countries. All samples subject histopathological evaluation, DNA quality control, HPV-DNA detection. Samples containing further HPV...

10.1093/jnci/djv403 article EN JNCI Journal of the National Cancer Institute 2016-01-28

It is now well established that infection with oncogenic human papillomavirus (HPV) types the necessary cause of cervical cancer (CC) and its immediate precursor intraepithelial neoplasia 3. However, HPV alone may not be sufficient to CC, other exogenous endogenous factors exist that, in conjunction HPV, influence risk progression from CC. In this chapter, we review evidence for role parity, oral contraceptive (OC) use, tobacco smoking We also discuss limitations methodologic problems...

10.1093/oxfordjournals.jncimonographs.a003477 article EN JNCI Monographs 2003-06-01

OBJECTIVE. Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown prevent type-specific infection and associated clinical disease. We conducted noninferiority immunogenicity study bridge the efficacy findings in young women preadolescent adolescent girls boys, who represent primary target for vaccination. METHODS. enrolled 506 510 boys (10–15 years age) 513 (16–23 age). Participants...

10.1542/peds.2006-0461 article EN PEDIATRICS 2006-11-01
Coming Soon ...